Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C1 | P04150 | 9/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 3/20 | 0.48 |
| ▸ | TP53 | P04637 | 3/20 | 0.48 |
| ▸ | ADRB2 | P07550 | 2/20 | 0.48 |
| ▸ | ADRB1 | P08588 | 2/20 | 0.48 |
| ▸ | ADRB3 | P13945 | 2/20 | 0.48 |
| ▸ | PKM | P14618 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6981758 | 0.91 | NR3C1 (0.56) | NR3C1SMN1; SMN2MAPTTP53ADRB2 | |
| SCHEMBL6985317 | 0.86 | NR3C1 (0.58) | NR3C1SMN1; SMN2MAPTTP53ADRB2 | |
| Hydrochloric Acid SCHEMBL6983739 | 0.85 | NR3C1 (0.58) | NR3C1SMN1; SMN2MAPTTP53ADRB2 | |
| SCHEMBL6985366 | 0.84 | NR3C1 (0.66) | NR3C1MAPTTP53LMNA | |
| SCHEMBL6977969 | 0.84 | NR3C1 (0.56) | NR3C1SMN1; SMN2MAPTTP53ADRB2 | |
| SCHEMBL6979190 | 0.83 | NR3C1 (0.56) | NR3C1SMN1; SMN2MAPTTP53ADRB2 | |
| SCHEMBL6976880 | 0.83 | NR3C1 (0.55) | NR3C1SMN1; SMN2MAPTTP53PKM | |
| SCHEMBL6980538 | 0.82 | NR3C1 (0.56) | NR3C1SMN1; SMN2MAPTTP53LMNA | |
| SCHEMBL6983048 | 0.82 | NAMPT (0.41) | NR3C1MAPTTP53PKMLMNA | |
| SCHEMBL6984553 | 0.80 | NR3C1 (0.56) | NR3C1MAPTTP53PKMLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0991624-B1 | PHENYLALKYL DERIVATIVES WITH THROMBIN-INHIBITING EFFECT | BOEHRINGER INGELHEIM PHARMA (DE) | 2003-11-19 | — | — | EP | disclosed |
| US-6300342-B1 | FOR THERAPY OR INHIBITING THROMBUS FORMATION; FOR THERAPY OF FIBRIN-DEPENDENT INFLAMMATORY CONDITION | BOEHRINGER INGELHEIM PHARM KG (DE) | 2001-10-09 | — | — | US | disclosed |